Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double Blind, Controlled Mechanistic Study of Rituximab and Belimumab Combination Therapy in PR3 ANCA-associated Vasculitis

NCT03967925 is registered in ClinicalTrials.gov with Rachel Jones as lead sponsor.

NCT NCT03967925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03967925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double Blind, Controlled Mechanistic Study of Rituximab and Belimumab Combination Therapy in PR3 ANCA-associated Vasculitis
Lead sponsor
Rachel Jones
Phase
Phase 2
Overall status
Unknown status
Start date
February 1, 2019
Completion date
November 30, 2023
Enrollment
31 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

anca associated vasculitis, granulomatosis with polyangiitis